Dr. Brian Abbott MD
Medical Director of Hematology, Big Sky Oncology
Member of the Healthcare Council
Council Member Biography
Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology (Benefis Health System) and Sletten Cancer Institute in Great Falls, Montana. He is also Medical Director of the Palliative Medicine program. Dr. Abbott's specialties include acute and chronic leukemia (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin's and Hodgkin's Lymphoma, myelomas, bone and marrow transplants (BMT), myelodysplastic syndrome (MDS), and aplastic anemia. He also treats significant numbers of lung, colon, and breast cancer patients. Dr. Abbott has experience in consulting with hedge fund and venture capital firms regarding biotechnology start-up investment opportunities and due diligence. He has a special interest in consulting with pharmaceutical companies regarding acquisitions and in design of clinical trials, and providing the insight of a physician who has worked in academic and community oncology practice environments. (This is me - Update Profile)
Employment History
- 2007 - Unspecified
- Medical Director of Hematology, Big Sky Oncology
- 2007 - Unspecified
- Medical Director, Hematology Division, Sletten Cancer Institute
- 2005 - 2006
- Assistant Professor of Medicine, University of Colorado Health Sciences Center
GLG NewsSM Analyses by Brian Abbott(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
TREANDA for CLL could be a winner
May 19, 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
-
National healthcare? Better find a new pool of physicians
May 19, 2008
Look to England's example for ways to solve America's health-care problem | www.sltrib.com
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
-
Medicare: heading toward a crisis
May 19, 2008
Loss of Doctors Leaves Patients Waiting | www.redorbit.com
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
-
The Vidaza survival benefit news is a positive for MGI Pharma's Dacogen
November 19, 2007
Vidaza vs Dacgoen for MDS | www.newratings.com
There is no reason to believe Dacogen is inferior to Vidaza. In some studies, Dacogen seems to produce a deeper quality of response, and may also prove more beneficial in AML.
-
Revlimid benefits seem overstated in non-5Q minus MDS
November 19, 2007
Phase II study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q | bloodjournal.hematologylibrary.org
Revlimid benefits are often over-stated in non-5Q minus MDS. The cost is a hurdle for many patients with poor prescription plans. Vidaza and Dacogen seem superior in my experience for higher risk patients.
Leading institutions connect with Brian Abbott through GLG
GLG Study Groups with Brian Abbott(?)
| Study Group Name | No. Members |
|---|---|
| TMT Council Members in Member Programs | 16437 |
| Technology Council Members in Member Programs | 8640 |
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Oncologists (US) | 2241 |
GLG Live Meetings with Brian Abbott(?)
Brian Abbott has not participated in any GLG Live Meetings.